ASCO 2022 | Managing CRS and neurotoxicities associated with CAR-T in ZUMA-3
Bijal Shah
• 4 Jun 2022
Bijal Shah, MD, Moffitt Cancer Center, Tampa, FL, discusses toxicities associated with CAR T-cell therapies in patients with B-cell acute lymphoblastic leukemia (B-ALL) enrolled in the Phase III ZUMA-3 trial (NCT02614066), and highlights the importance of early intervention with tocilizumab in patients developing cytokine release syndrome (CRS). Reduced severity and duration of neurotoxicity were associated with treatment using corticosteroids. This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.
